RxDoctor Payments Data

Aravinda Reddy, MD

Nephrology · Elizabeth, NJNPI 1497948640

Payments from drug & device makers

$567in general payments, 2019–2025

Across 17 payments — averaging $33.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$162
  • Amgen$124
  • Otsuka America Pharmaceutical, Inc.$96
  • Novo Nordisk$41
  • Bard Peripheral Vascular, Inc.$35
  • AstraZeneca$26
  • plus $83 from 5 others

What the payments were for

  • Travel & lodging$356%
  • Food & beverage$43677%
  • Education$9617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$567 in reported general payments places this provider in the 40th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$373,662
Medicare patients
305
Services billed
2,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol91$78,112
EliquisApixaban54$41,087
JanuviaSitagliptin Phosphate39$32,144
JardianceEmpagliflozin31$24,029
ProsolParenteral Amino Acid 20% No.1149$24,006
LokelmaSodium Zirconium Cyclosilicate16$13,184
Spiriva RespimatTiotropium Bromide16$8,439
Sevelamer Carbonate49$7,268
BrilintaTicagrelor24$5,409
SymbicortBudesonide/Formoterol Fumarate22$5,380
DapagliflozinDapagliflozin Propanediol11$5,372
Clonidine20$4,838
Incruse ElliptaUmeclidinium Bromide12$3,976
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,661
Diclofenac Sodium17$2,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma, Brilinta, Symbicort$26$102,086153 claims
Boehringer IngelheimJardiance, Spiriva Respimat$16$32,46847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 413 nephrology providers in New Jersey.

Other nephrology in Elizabeth

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →